Tag: Opthea Limited

Browse exclusive Tags!

Opthea Receives A$8.8 Million R&D Tax Credit for OPT-302 Development in Wet AMD – Strengthening Cash Position, Australia

Opthea receives A$8.8 million R&D tax credit for OPT-302 development in wet AMD, strengthening cash position. Learn more about their innovative approach to treating retinal diseases.

Opthea Announces Breakthrough Therapy Presentation on Sozinibercept for Age-Related Macular Degeneration at FLORetina Congress, Australia

Opthea to unveil breakthrough therapy for age-related macular degeneration at FLORetina Congress. Leading experts to present innovative treatment at prestigious event.

Popular

Opthea Receives A$8.8 Million R&D Tax Credit for OPT-302 Development in Wet AMD – Strengthening Cash Position, Australia

Opthea receives A$8.8 million R&D tax credit for OPT-302 development in wet AMD, strengthening cash position. Learn more about their innovative approach to treating retinal diseases.

Subscribe

spot_imgspot_img